Mounjaro®
Starting from £179.99/mo
Start journey Learn moreTirzepatide is not available over the counter in the UK. It is a Prescription-Only Medicine (POM), meaning a qualified prescriber must assess your suitability and issue a prescription before any pharmacy can dispense it — regardless of where you see it advertised. That legal requirement applies to every dose, every refill, and every route, private or NHS. Anyone offering tirzepatide without that clinical step is breaking UK medicines law.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The short answer is that UK law does not allow it. Tirzepatide was classified as a Prescription-Only Medicine when the MHRA first licensed it, and that classification has not changed. The NHS medicines page on tirzepatide explains the medicine's profile clearly: it works by mimicking two gut hormones, GIP and GLP-1, slowing gastric emptying and reducing appetite. That mechanism is potent, which is precisely why the regulatory framework requires a prescriber to assess contraindications, review your current medicines, confirm your BMI, and set the right starting point before dispensing begins.
There are also meaningful clinical risks to starting without oversight. Tirzepatide can reduce the absorption of oral contraceptives during the first four weeks of treatment and after each dose increase, and it interacts with certain blood-sugar-lowering medicines. These are not abstract concerns, they are the reason a prescriber's review sits between you and the first pen.
So if a website is offering tirzepatide OTC, without asking for a consultation or a prescription, that is not a regulatory grey area. It is an illegal supply. The medicine could be counterfeit, mislabelled, or stored incorrectly. The MHRA has documented hospitalisations linked to fake weight-loss pens containing insulin. Report any suspect seller at the MHRA's Yellow Card site, there is a dedicated route for flagging illegitimate medicines sellers.
No. Every licensed strength of tirzepatide in the UK (from the 2.5 mg starter pen through to 15 mg) carries the same POM classification. There is no lower dose that crosses into pharmacy or general sale territory, and there is no oral or alternative form of tirzepatide that sits outside the prescription requirement. Mounjaro is the brand name for the medicine in the UK; you may see tirzepatide and Mounjaro used interchangeably, and both refer to the same prescription-only product.
Some readers arrive at this question after seeing references to tirzepatide sold without a prescription in other countries. Those products are not licensed for sale in the UK, and importing a POM for personal use without a valid UK prescription sits in a legally and clinically uncertain space. It also bypasses the safety steps that catch, for example, a thyroid condition or a history of pancreatitis that would make tirzepatide unsuitable.
For context on what pricing looks like through a legitimate private route, the cost guide for Mounjaro in the UK covers how private prices are structured and what the prescription and clinical oversight components actually include.
For adults who meet the licensed eligibility criteria (broadly, a BMI of 30 or above, or 27 or above with at least one weight-related health condition such as high blood pressure or type 2 diabetes) a private prescription from a regulated UK pharmacy is a fully lawful and clinically supervised route. It does not require an NHS referral, and there is no waiting list in the private setting.
The process at a GPhC-registered pharmacy involves a clinical consultation, photo-ID and live weight verification, a review of your medical history, and a prescriber's assessment before any medicine is approved. At nume, a named GPhC-registered Independent Prescriber reads every consultation the same day it is submitted, Monday to Friday, order by 12pm and, once approved, your treatment is dispatched the same day. (If you happen to order on a payday Friday before a bank holiday, the timing still holds on the next working day.) Delivery arrives in plain, unbranded packaging via DPD.
You can verify any UK online pharmacy (including ours, registered under number 9012878) on the GPhC register. That check takes about thirty seconds and is the clearest signal that a pharmacy is operating within UK law. The about us page explains how our clinical team is structured if you want more detail on who reviews consultations.
If you would like to understand how weight-loss treatment works at nume before going further, that is a good place to start. When you are ready to speak to a prescriber, the free consultation page is the right next step.
Report it. The MHRA takes illegal medicine supply seriously and has enforcement powers, the Yellow Card scheme accepts reports from the public, not just healthcare professionals. When you report, note the website address, the price, and any product details you can see. You do not need to have bought anything to make a report.
Beyond reporting, the practical guidance is to avoid purchasing. Fake pens have been found to contain substances including insulin, with no labelling to that effect. Even pens that contain genuine tirzepatide but have been stored outside the recommended cold chain (refrigeration between 2 and 8 degrees Celsius, with only a limited window at room temperature per the Patient Information Leaflet) may be degraded and ineffective, or unpredictably potent.
The NICE appraisal of tirzepatide (TA1026) describes it as a medicine with substantial clinical evidence behind it. That evidence was gathered under supervised conditions with consistent dosing and monitoring, including at the 10 mg maintenance dose that many patients reach after titration. Replicating those outcomes without clinical oversight, and certainly without genuine medicine, is not possible. The prescription requirement exists precisely because the medicine works, and because getting it wrong has consequences. Our guidance on tirzepatide at the 30-unit pen level and on the tirzepatide L pen explains how dose steps are managed within a supervised treatment plan.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.